Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06462729 · ClinicalTrials.gov registry record · Phase 1
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
A Phase 1 study of Degenerative Disc Disease and Lumbar Spine Degeneration, sponsored by Locate Bio Pty.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT06462729 is a Phase 1 study of Degenerative Disc Disease and Lumbar Spine Degeneration that is actively recruiting participants, run by Locate Bio Pty. The registered enrollment target is 40 participants, below the 168-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06462729, a Phase 1 study of Degenerative Disc Disease and Lumbar Spine Degeneration, is actively recruiting participants, sponsored by Locate Bio Pty.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of LDGraft (investigational device) compared to 100% human tissue product allograft bone (control) when applied in an ALIF procedure in the treatment of patients with lumbar degenerative disc disease (DDD).
Conditions Studied
Interventions
- DEVICE LDGraft
- OTHER Allograft Bone
Study Locations (3)
New South Wales
- Newcastle Private Hospital - Newcastle
- Macquarie University - Sydney
Indiana
- Orthopaedics NorthEast - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06462729
The ClinicalTrials.gov registry entry for NCT06462729 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (76% lower). The listed sponsor is Locate Bio Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Degenerative Disc Disease appearing as the primary indexed condition, and to 2 interventions - of which LDGraft is the first listed.
NCT06462729 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New South Wales, Indiana.
Frequently Asked Questions
What is clinical trial NCT06462729 about?
NCT06462729 is a clinical study titled "LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)". The objective of this study is to evaluate the safety and effectiveness of LDGraft (investigational device) compared to 100% human tissue product allograft bone (control) when applied in an ALIF procedure in the treatment of patients with lumbar degenerative disc disease (DDD).
What is the current status of trial NCT06462729?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-11-12. Estimated completion is 2027-12.
What conditions does trial NCT06462729 study?
This clinical trial studies the following conditions: Degenerative Disc Disease, Lumbar Spine Degeneration, Spine Disease, Lumbar Disc Disease.
What interventions are being tested in trial NCT06462729?
The interventions under investigation include: LDGraft (DEVICE), Allograft Bone (OTHER).
Who is sponsoring clinical trial NCT06462729?
This trial is sponsored by Locate Bio Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06462729 being conducted?
This trial has 3 study locations across Indiana, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Disc Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
OssDsign® Spine Registry Study ("Propel")
RECRUITING
-
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
RECRUITING · Phase 3
-
Investigation of DEXA-C Anterior Cervical Interbody System
RECRUITING · NA
-
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.